Rapport Therapeutics announced that RAP-219, a drug for focal onset seizures, demonstrated sustained seizure reduction during an 8-week follow-up after an 8-week treatment in its Phase 2a trial. The drug showed a 90% median reduction in clinical seizures in weeks 9-12 and a 59% reduction in weeks 13-16, supported by its long half-life of about 22 days. RAP-219 was well tolerated with minimal adverse events. Phase 3 trials are planned to start in Q2 2026, with further data expected from ongoing long-term safety and other neurological disorder trials.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
